Skip to main content
CDT
NASDAQ Life Sciences

Major Shareholder Group Exits Entire 43.79% Stake in CDT Equity, Selling Over $2.98M in Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.14
Mkt Cap
$5.587M
52W Low
$0.671
52W High
$610
52W Position info
70% above low
Off High info
100% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CDT sits 70% above its 52-week low of $0.671.

Summary

A major investor group, Mark Taylor and associated entities, has fully exited its 43.79% stake in CDT Equity Inc., selling over $2.98 million worth of shares, which is more than half of the company's market cap.


Key Events · Ownership and Investor Activity · CDT

  • Major Shareholder Exit

    The Mark Taylor-led investor group, which previously held a 43.79% beneficial ownership, has fully liquidated its entire stake in CDT Equity Inc.

  • Significant Share Sale

    The group sold a total of 2,068,000 shares for approximately $2.98 million on June 18, 2026. This represents over 50% of the company's current market capitalization.

  • Timing with Positive News

    The liquidation occurred on the same day the company announced a $127.5 million valuation for its stake in Sarborg Limited, potentially indicating the group sold into market strength.

  • Impact on Ownership Structure

    The reporting persons (Mark Taylor, Prospect Capital Securities Ltd, and Prospect Finance Ltd) no longer beneficially own more than 5% of the outstanding common stock.


Analysis · CDT · Life Sciences

An investor group led by Mark Taylor, which previously held a significant 43.79% stake in CDT Equity Inc., has fully liquidated its position. The group sold a total of 2,068,000 shares for approximately $2.98 million, representing over 50% of the company's current market capitalization. This complete exit by a major shareholder group is a strong negative signal, particularly given the company's ongoing financial challenges, including a going concern warning and Nasdaq deficiency. The sales occurred on the same day as a positive news release regarding an investment valuation, suggesting the group may have capitalized on a temporary uplift to facilitate their exit.

At the time of this filing, CDT was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.67 to $610.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDT - Latest Insights

CDT
Jul 31, 2026, 5:29 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $2.92
Real-time Price: $3.62 info
Change: +$0.700 (+24%) info
Market Cap: $2.844M info
CDT
Jul 31, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.87
Real-time Price: $3.62 info
Change: +$0.745 (+26%) info
Market Cap: $2.844M info
CDT
Jul 16, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.322
Real-time Price: $3.62 info
Change: Reverse Stock Split info
Market Cap: $2.844M info
CDT
Jul 16, 2026, 8:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.2815
Real-time Price: $3.62 info
Change: Reverse Stock Split info
Market Cap: $2.844M info
CDT
Jul 15, 2026, 4:51 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3503
Real-time Price: $3.62 info
Change: Reverse Stock Split info
Market Cap: $2.844M info